Polarean Imaging PLC Extension of Warrants (4060B)
2023年6月2日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMPOLX
RNS Number : 4060B
Polarean Imaging PLC
02 June 2023
Polarean Imaging Plc
("Polarean" or the "Company")
Extension of Warrants
Polarean Imaging plc (AIM: POLX), the medical imaging technology
company, announces that the Board has approved the extension of the
expiry date of 852,822 warrants over ordinary shares in the Company
(the "Warrants"), held by Mr. Kenneth West, Chairman of the
Company, to 31 July 2023 from their current expiry date of 2 June
2023. The Warrants were issued on 3 June 2013 to a consulting group
for which Mr. West was a partner and subsequently assigned to Mr.
West. All other terms of the Warrants remain unchanged.
The extension of the expiry date for the Warrants amounts to a
related party transaction within the meaning of the AIM Rules for
Companies. The Directors who are independent of the related party
transaction (being all the Directors of the Company other than Mr.
Kenneth West) having consulted with Stifel, the Company's nominated
adviser, consider this proposed extension of the expiry date to be
fair and reasonable insofar as the shareholders of the Company are
concerned.
Mr. Kenneth West holds a total of 2,801,084 warrants over
ordinary shares of the Company. In addition, Kenneth also holds
options for 2,263,218 shares and 475,594 ordinary shares.
Enquiries:
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Richard Hullihen, Chief Executive Via Walbrook PR
Officer
Kenneth West, Chairman
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw
(Healthcare
Investment Banking)
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0)
7867 984 082
About Polarean ( www.polarean.com)
The Company and its wholly owned subsidiary, Polarean, Inc.
(together the "Group") are revenue-generating, medical imaging
technology companies operating in the high-resolution medical
imaging space. Polarean aspires to revolutionise pulmonary medicine
by bringing the power and safety of MRI to the respiratory
healthcare community in need of new solutions to evaluate lung
ventilation, diagnose disease, characterise disease progression,
and monitor response to treatment. By researching, developing, and
commercialising novel imaging solutions with a non-invasive and
radiation-free functional imaging platform. Polarean's vision is to
help address the global unmet medical needs of more than 500
million patients worldwide suffering with chronic respiratory
disease. Polarean is a leader in the field of hyperpolarisation
science and has successfully developed the first and only
hyperpolarised MRI contrast agent to be approved in the United
States. On Dec. 23, 2022, the FDA granted approval for Polarean's
first drug device combination product, XENOVIEW(TM) (Xenon Xe(129)
hyperpolarised). Xe(129) MRI is also currently being studied for
visualisation and quantification of gas exchange regionally in the
smallest airways of the lungs, across the alveolar tissue membrane,
and into the pulmonary bloodstream for future clinical
indications.
XENOVIEW IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Risk of Decreased Image Quality from Supplemental Oxygen:
Supplemental oxygen administered simultaneously with XENOVIEW
inhalation can cause degradation of image quality. For patients on
supplemental oxygen, withhold oxygen inhalation for two breaths
prior to XENOVIEW inhalation, and resume oxygen inhalation
immediately following the imaging breath hold.
Risk of Transient Hypoxia: Inhalation of an anoxic gas such as
XENOVIEW may cause transient hypoxemia in susceptible patients.
Monitor all patients for oxygen desaturation and symptoms of
hypoxemia and treat as clinically indicated.
Adverse Reactions
Adverse Reactions in Adult Patients: The adverse reactions (>
one patient) in efficacy trials were oropharyngeal pain, headache,
and dizziness. Adverse Reactions in Pediatric and Adolescent
Patients: In published literature in pediatric patients aged 6 to
18, transient adverse reactions were reported: blood oxygen
desaturation, heart rate elevation, numbness, tingling, dizziness,
and euphoria. In at least one published study of pediatric patients
aged 6 to 18 years, transient decrease in SpO2% and transient
increase in heart rate was reported following hyperpolarized xenon
Xe 129 administration. XENOVIEW is not approved for use in
pediatric patients less than 12 years of age.
Please see full prescribing information at www.xenoview.net
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRUAVVRORUNRAR
(END) Dow Jones Newswires
June 02, 2023 02:00 ET (06:00 GMT)
Polarean Imaging (LSE:POLX)
過去 株価チャート
から 4 2024 まで 5 2024
Polarean Imaging (LSE:POLX)
過去 株価チャート
から 5 2023 まで 5 2024